Efficacy News and Research

RSS
Discovery of IDE may lead to new treatment approaches for diabetes

Discovery of IDE may lead to new treatment approaches for diabetes

New antibiotic proves effective in treating serious bacterial skin and skin-structure infections

New antibiotic proves effective in treating serious bacterial skin and skin-structure infections

CenterVue's next generation Macular Integrity Assessment receives FDA clearance

CenterVue's next generation Macular Integrity Assessment receives FDA clearance

Comparative study shows ultrasonic Bonescalpel makes spine surgery safe, efficient

Comparative study shows ultrasonic Bonescalpel makes spine surgery safe, efficient

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

PsiOxus Therapeutics presents positive study results of anti-cancer vaccine Enadenotucirev at ASCO Annual Meeting

PsiOxus Therapeutics presents positive study results of anti-cancer vaccine Enadenotucirev at ASCO Annual Meeting

NeuroVive extends collaboration with Hospices Civils de Lyon

NeuroVive extends collaboration with Hospices Civils de Lyon

Thrasos presents positive results of THR-184 compound for treatment of acute kidney injury

Thrasos presents positive results of THR-184 compound for treatment of acute kidney injury

EC approves extension of INVEGA antipsychotic drug to include adolescents aged 15 years and older

EC approves extension of INVEGA antipsychotic drug to include adolescents aged 15 years and older

Autifony Therapeutics awarded £2.2 million to progress first-in-class drug for tinnitus into Phase IIa study

Autifony Therapeutics awarded £2.2 million to progress first-in-class drug for tinnitus into Phase IIa study

Screening helped prevent nearly half a million colorectal cancer cases in the U.S.

Screening helped prevent nearly half a million colorectal cancer cases in the U.S.

Cerenis’ SAMBA and MODE Phase II Studies Meet Primary Endpoints for Treatment of FPHA, HoFH

Cerenis’ SAMBA and MODE Phase II Studies Meet Primary Endpoints for Treatment of FPHA, HoFH

CRS-207 and chemotherapy combination Phase 1b trial data for unresectable MPM presented at ASCO 2014

CRS-207 and chemotherapy combination Phase 1b trial data for unresectable MPM presented at ASCO 2014

Alkermes initiates second ALKS 3831 Phase 2 clinical study for treatment of schizophrenia

Alkermes initiates second ALKS 3831 Phase 2 clinical study for treatment of schizophrenia

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Updated data from ImmunoCellular ICT-107 trial in patients with newly diagnosed GBM presented at ASCO 2014

Updated data from ImmunoCellular ICT-107 trial in patients with newly diagnosed GBM presented at ASCO 2014

ImmunoGen reports favorable clinical results from STARLYTE Phase II trial of SAR3419 for DLBCL

ImmunoGen reports favorable clinical results from STARLYTE Phase II trial of SAR3419 for DLBCL

Memorial Sloan Kettering Cancer Center, Quest Diagnostics partner for cancer tests

Memorial Sloan Kettering Cancer Center, Quest Diagnostics partner for cancer tests

New cancer panel holds promise in detection of previously undetected viral, cancer mutations

New cancer panel holds promise in detection of previously undetected viral, cancer mutations

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.